Key result
Mebudipine cuts big endothelin-1 ~55% and improves heart failure signs in a doxorubicin-induced rat model.
Why the study?
Mebudipine's negative chronotropic effects without considerable negative inotropy may suit heart failure pharmacotherapy, prompting investigation of its actions in a rat model of heart failure.
Does mebudipine improve biochemical and clinical signs of heart failure in a doxorubicin-induced rat model?
Does mebudipine improve biochemical and clinical signs of heart failure in a doxorubicin-induced rat model?
Mebudipine, a novel dihydropyridine calcium-channel blocker, palliated biochemical and clinical signs of doxorubicin-induced heart failure in rats, similar to amlodipine.
May support mebudipine in doxorubicin HF models; leaves open clinical translation.
Background: Mebudipine, a dihydropyridine calcium-channel blocker (CCB), shows greater time- and voltage-dependent inhibitory effects than nifedipine. Its significant negative chronotropic effects without having considerable negative inotropic properties may make it a suitable candidate for the pharmacotherapy of heart failure (HF). This study aimed to investigate the possible beneficial action of mebudipine in a rat model of HF. Methods: The present study carried out in the Department of Pharmacology at the Iran University of Medical Sciences during the years of 2009-2011. An experimental model of HF was induced in male Wistar rats using doxorubicin (DOX). The rats were divided into five groups with seven animals in each group: normal control group, DOX-induced HF control groups, and treatment groups. The animals were administered DOX for 15 days. A consistent deterioration occurred after a four-week rest period. The animals were then treated with intraperitoneal mebudipine (0.5 mg/kg) and intraperitoneal amlodipine (0.35 mg/kg), as well as an equal volume of distilled water for 15 days. The plasma levels of big endothelin-1 (BET-1), creatine kinase-myocardial band (CK-MB), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and alanine aminotransferase (ALT), as well as the clinical status (heart rate and blood pressure), were assessed before and after treatment. Statistical analysis was performed with SPSS software using parametric and nonparametric ANOVA. Results: Mebudipine and amlodipine reversed the increased plasma BET-1 values in the treated animals when compared with the HF control group (0.103 and 0.112 vs 0.231 pg/mL, respectively). The increased plasma levels of AST, ALT, CK-MB, and LDH were also reversed in the HF animals that received mebudipine or amlodipine. Conclusion: The administration of mebudipine to HF animals, akin to amlodipine, palliated the clinical and biochemical signs of the disease in the present study. The abstract was presented in the Iranian Congress of Physiology and Pharmacology as a poster and published in the Scientific Information Database as a supplement (2015; Vol 22).
No takes yet. Share an insight, caveat, or question.
Aali et al. (2021) studied Doxorubicin-induced heart failure (n=35). Mebudipine vs. Distilled water (HF control) was evaluated on Plasma big endothelin-1 (BET-1) values (pg/mL) (p=<0.001). Mebudipine significantly reversed the increased plasma big endothelin-1 values (0.103 vs 0.231 pg/mL) and ameliorated clinical and biochemical signs in a rat model of doxorubicin-induced heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: